Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis | Zendy

N. Jewel Samadder | Zendy; Deborah W. Neklason | Zendy; Kenneth M. Boucher | Zendy; Kathryn R. Byrne | Zendy; Priyanka Kanth | Zendy; Wade S. Samowitz | Zendy; David A. Jones | Zendy; Sean V. Tavtigian | Zendy; Michelle W. Done | Zendy; Therese Berry | Zendy; Kory Jasperson | Zendy; Lisa M. Pappas | Zendy; Laurel Smith | Zendy; Danielle Sample | Zendy; Rian Davis | Zendy; Matthew K. Topham | Zendy; Patrick M. Lynch | Zendy; Elena G. Strait | Zendy; Wendy McKin | Zendy; Randall W. Burt | Zendy; Scott K. Kuwada | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis

Author(s) -

N. Jewel Samadder,

Deborah W. Neklason,

Kenneth M. Boucher,

Kathryn R. Byrne,

Priyanka Kanth,

Wade S. Samowitz,

David A. Jones,

Sean V. Tavtigian,

Michelle W. Done,

Therese Berry,

Kory Jasperson,

Lisa M. Pappas,

Laurel Smith,

Danielle Sample,

Rian Davis,

Matthew K. Topham,

Patrick M. Lynch,

Elena G. Strait,

Wendy McKin,

Randall W. Burt,

Scott K. Kuwada

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.2522

Subject(s) - medicine , familial adenomatous polyposis , gastroenterology , duodenal cancer , erlotinib , randomized controlled trial , placebo , duodenum , colorectal cancer , cancer , pathology , epidermal growth factor receptor , alternative medicine

Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal neoplasia is difficult and chemoprevention has not been successful.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research